BNP Paribas Financial Markets Buys 15,872 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)

BNP Paribas Financial Markets lifted its position in Capricor Therapeutics Inc (NASDAQ:CAPR) by 868.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 17,699 shares of the biotechnology company’s stock after purchasing an additional 15,872 shares during the period. BNP Paribas Financial Markets’ holdings in Capricor Therapeutics were worth $269,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Main Street Financial Solutions LLC grew its holdings in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter worth about $133,000. Rhumbline Advisers purchased a new stake in shares of Capricor Therapeutics during the second quarter worth about $147,000. The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics in the third quarter worth about $161,000. Finally, FMR LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at about $370,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Stock Performance

Shares of CAPR stock opened at $13.26 on Monday. The company has a market capitalization of $602.93 million, a price-to-earnings ratio of -12.51 and a beta of 3.98. Capricor Therapeutics Inc has a one year low of $3.52 and a one year high of $23.40. The company’s 50-day moving average is $18.42 and its 200 day moving average is $10.07.

Insider Activity

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were bought at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 12.00% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 target price on the stock. Cantor Fitzgerald increased their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Maxim Group raised their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.